These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 17597746)

  • 1. Neurophysiology: stressful pacemaking.
    Bean BP
    Nature; 2007 Jun; 447(7148):1059-60. PubMed ID: 17597746
    [No Abstract]   [Full Text] [Related]  

  • 2. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease.
    Chan CS; Guzman JN; Ilijic E; Mercer JN; Rick C; Tkatch T; Meredith GE; Surmeier DJ
    Nature; 2007 Jun; 447(7148):1081-6. PubMed ID: 17558391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease: return of an old prime suspect.
    Sulzer D; Schmitz Y
    Neuron; 2007 Jul; 55(1):8-10. PubMed ID: 17610813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What causes the death of dopaminergic neurons in Parkinson's disease?
    Surmeier DJ; Guzman JN; Sanchez-Padilla J; Goldberg JA
    Prog Brain Res; 2010; 183():59-77. PubMed ID: 20696315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular mechanisms of dopamine toxicity.
    Barzilai A; Daily D; Zilkha-Falb R; Ziv I; Offen D; Melamed E; Shirvan A
    Adv Neurol; 2003; 91():73-82. PubMed ID: 12442665
    [No Abstract]   [Full Text] [Related]  

  • 6. Potential nondopaminergic drugs for Parkinson's disease.
    Silverdale MA; Fox SH; Crossman AR; Brotchie JM
    Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686
    [No Abstract]   [Full Text] [Related]  

  • 7. mtDNA clock runs out for dopaminergic neurons.
    Manfredi G
    Nat Genet; 2006 May; 38(5):507-8. PubMed ID: 16642013
    [No Abstract]   [Full Text] [Related]  

  • 8. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.
    Surmeier DJ; Guzman JN; Sanchez-Padilla J
    Cell Calcium; 2010 Feb; 47(2):175-82. PubMed ID: 20053445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microglial activation is not prevented by tacrolimus but dopamine neuron damage is reduced in a rat model of Parkinson's disease progression.
    Wright AK; Miller C; Williams M; Arbuthnott G
    Brain Res; 2008 Jun; 1216():78-86. PubMed ID: 18495090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Abnormal neurotransmission in neurological diseases (author's transl)].
    Toru M
    Tanpakushitsu Kakusan Koso; 1979; 24(2):150-9. PubMed ID: 35816
    [No Abstract]   [Full Text] [Related]  

  • 12. A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease.
    Chan CS; Gertler TS; Surmeier DJ
    Mov Disord; 2010; 25 Suppl 1():S63-70. PubMed ID: 20187241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A channel to neurodegeneration.
    Deutch AY; Winder DG
    Nat Med; 2006 Jan; 12(1):17-8. PubMed ID: 16397545
    [No Abstract]   [Full Text] [Related]  

  • 14. Individual dopaminergic neurons show raised iron levels in Parkinson disease.
    Oakley AE; Collingwood JF; Dobson J; Love G; Perrott HR; Edwardson JA; Elstner M; Morris CM
    Neurology; 2007 May; 68(21):1820-5. PubMed ID: 17515544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bilobalide inhibits 6-OHDA-induced activation of NF-kappaB and loss of dopaminergic neurons in rat substantia nigra.
    Li LY; Zhao XL; Fei XF; Gu ZL; Qin ZH; Liang ZQ
    Acta Pharmacol Sin; 2008 May; 29(5):539-47. PubMed ID: 18430361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glial reactions in Parkinson's disease.
    McGeer PL; McGeer EG
    Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Membrane-permeable Bcl-xL prevents MPTP-induced dopaminergic neuronal loss in the substantia nigra.
    Dietz GP; Stockhausen KV; Dietz B; Falkenburger BH; Valbuena P; Opazo F; Lingor P; Meuer K; Weishaupt JH; Schulz JB; Bähr M
    J Neurochem; 2008 Feb; 104(3):757-65. PubMed ID: 17995935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
    Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
    Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson's disease models.
    Takeuchi H; Yanagida T; Inden M; Takata K; Kitamura Y; Yamakawa K; Sawada H; Izumi Y; Yamamoto N; Kihara T; Uemura K; Inoue H; Taniguchi T; Akaike A; Takahashi R; Shimohama S
    J Neurosci Res; 2009 Feb; 87(2):576-85. PubMed ID: 18803299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect-pathway neurons lose their spines in Parkinson disease.
    Gerfen CR
    Nat Neurosci; 2006 Feb; 9(2):157-8. PubMed ID: 16439979
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.